Advancing BNCT
An Emerging Precision Medicine Modality to Treat Solid Tumors
about BNCT
BNCT holds the potential to overcome poor survival rates for patients with a variety of cancers
Boron neutron capture therapy (BNCT) was initially conceived in the early 20th century. Due to recent advances in boron medicinal chemistry and targeted delivery of safe neutrons, the technology has shown great promise for treating patients with solid tumors.
1
Boron medicines are administered intravenously
2
Boron medicines preferentially accumulate in tumor cells
3
Tumor is precisely irradiated with safe, low-energy neutrons
4
Interaction of safe neutrons with boron medicines releases alpha particles that selectively destroy the tumor
Why BNCT?
Despite improvements in cancer outcomes over recent decades, there is still a high unmet clinical need for effective treatments. Cytotoxic drugs, traditional radiation therapies and immunotherapies are limited in their effectiveness and can result in adverse side effects. Boron neutron capture therapy is a precision medicine approach to destroy cancerous cells while leaving healthy cells unharmed.
Highly precise
Together with advanced neutron delivery technologies, BNCT medicines have the ability to precisely target tumors
Potentially fewer treatments
Studies have shown that BNCT has the potential to destroy tumors in fewer treatments compared to other modalities
Low intrinsic toxicity
Boron medicines are designed to be non-toxic and are only activated by safe, low-energy neutrons at the tumor
A potentially safe, efficacious and convenient treatment option
Boron neutron capture therapy has been approved by the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan for unresectable advanced or recurrent head and neck cancer. Additional clinical research on BNCT is being conducted at 16 BNCT treatment centers worldwide.
The BNCT Ecosystem
To advance BNCT, we are building on generations of innovations in medicinal chemistry, neutron research and biopharmaceutical drug development. Through partnerships with biopharma companies and academic medical centers, we are working to expand access to this promising modality and establish U.S.-based BNCT treatment centers.
CONTACT US
Get Involved
If you would like to learn more about partnering to expand access to BNCT, please get in touch.